Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.34 |
| ▸ | ELANE | P08246 | 3/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542157 | 0.82 | TK1 (0.49) | PRKCATK1POLBGAANPSR1 | |
| SCHEMBL2438352 | 0.81 | TK1 (0.42) | PRKCATK1POLBGAANPSR1 | |
| SCHEMBL4953067 | 0.80 | PRKCA (0.41) | PRKCATK1POLBGAANPSR1 | |
| SCHEMBL5009120 | 0.79 | CYP4F2 (0.36) | CYP4F2CYP4A11 | |
| SCHEMBL194466 | 0.78 | TSHR (0.42) | PRKCATK1POLBGAANPSR1 | |
| SCHEMBL1685656 | 0.76 | BTN3A1 (0.44) | PRKCATK1POLBGAANPSR1 | |
| SCHEMBL14844517 | 0.76 | TK1 (0.39) | PRKCATK1POLBGAANPSR1 | |
| SCHEMBL15968333 | 0.76 | TK1 (0.39) | PRKCATK1POLBGAANPSR1 | |
| SCHEMBL5493183 | 0.76 | — | — | |
| SCHEMBL24961271 | 0.75 | TK1 (0.41) | PRKCATK1POLBGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300196-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | claimed |
| US-5475114-A | Angiotensin-11 antagonist; therapeutical agent used for treating hypertension and chronic heart failure | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-12-12 | — | — | US | disclosed |
| EP-0646584-A1 | PYRAZOLOTRIAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300196-A1 | MONOSACCHARIDE DERIVATIVES | HLA-DRB1, ASGR1, CSGALNACT1 | PRKCA 3410/4885TK1 2494/4885POLB 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.